Artelo Biosciences Awarded Composition of Matter Patent for Novel CBD Cocrystal
May 12, 2020 09:30 ET
|
Artelo Biosciences
LA JOLLA, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing proprietary therapeutics that target the...
Artelo Biosciences Reports Second Quarter Fiscal Year 2020 Financial Results and Provides Business Update
April 14, 2020 08:30 ET
|
Artelo Biosciences
LA JOLLA, Calif., April 14, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the...
Artelo Biosciences to Present at Biocom’s 10th Annual Global Life Sciences Partnering Conference
February 24, 2020 09:00 ET
|
Artelo Biosciences
LA JOLLA, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid...
Artelo Biosciences Announces NCI Grant of $4.2 Million to Stony Brook University to Advance FABP5 Inhibitor Cancer Program
February 03, 2020 08:30 ET
|
Artelo Biosciences
FABP5 platform under exclusive license to Artelo Biosciences NCI support provides further validation of next-generation target for cancer therapeutics LA JOLLA, Calif., Feb. 03, 2020 (GLOBE...
Artelo Biosciences to Present at the LSX World Congress in London
January 29, 2020 09:00 ET
|
Artelo Biosciences
LA JOLLA, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid...
Artelo Biosciences Reports First Quarter Fiscal Year 2020 Financial Results and Provides Business Update
January 14, 2020 08:00 ET
|
Artelo Biosciences
LA JOLLA, Calif., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the...
Artelo Biosciences Announces Appointment of Seasoned Finance and Industry Executive John W. Beck to Board of Directors
December 09, 2019 08:30 ET
|
Artelo Biosciences
LA JOLLA, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the...
Artelo Biosciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update
November 25, 2019 08:00 ET
|
Artelo Biosciences
LA JOLLA, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the...
Artelo Biosciences Announces Publication of Positive Non-Clinical Fatty Acid Binding Protein 5 Inhibitor Data in Peer-Reviewed Journal
November 18, 2019 08:30 ET
|
Artelo Biosciences
LA JOLLA, Calif., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid...
Artelo Biosciences to Present at the Annual Investival Showcase in London
November 14, 2019 09:00 ET
|
Artelo Biosciences
LA JOLLA, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid...